본문으로 건너뛰기
← 뒤로

[Thoracic oncology].

1/5 보강
Deutsche medizinische Wochenschrift (1946) 📖 저널 OA 0% 2023: 0/1 OA 2025: 0/5 OA 2026: 0/7 OA 2023~2026 2026 Vol.151(6) p. 264-268
Retraction 확인
출처

Reinmuth N

📝 환자 설명용 한 줄

Molecular diagnostics now also plays an essential role in treatment planning in the early and late stages of non-small cell lung cancer (NSCLC).

이 논문을 인용하기

↓ .bib ↓ .ris
APA Reinmuth N (2026). [Thoracic oncology].. Deutsche medizinische Wochenschrift (1946), 151(6), 264-268. https://doi.org/10.1055/a-2606-0502
MLA Reinmuth N. "[Thoracic oncology].." Deutsche medizinische Wochenschrift (1946), vol. 151, no. 6, 2026, pp. 264-268.
PMID 41802424 ↗
DOI 10.1055/a-2606-0502

Abstract

Molecular diagnostics now also plays an essential role in treatment planning in the early and late stages of non-small cell lung cancer (NSCLC). Following surgical resection or chemoradiotherapy, two targeted substances, osimertinib and alectinib, are now approved for adjuvant treatment. In resectable NSCLC, treatment with checkpoint inhibitors can be administered in an adjuvant, neoadjuvant, or perioperative setting. In metastatic stages, chemotherapy, immunotherapy, and targeted therapies are the therapeutic cornerstones with multiple drugs being tested in clinical studies. Immunotherapy has also become an established treatment option in the early stages of NSCLC and small cell lung cancer (SCLC). Based on the ADRIATIC study (durvalumab after simultaneous radiochemotherapy), this therapy was approved for SCLC, as it was for NSCLC.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (2)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반